Online citations, reference lists, and bibliographies.

Clinical Experience: Studies With HMG-CoA Reductase Inhibitors

H. Gylling, T. Miettinen
Published 2002 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Before the hydroxy-methyl glutaryl CoA (HMG-CoA) reductase inhibitor (statin) era, it was known from animal experiments and from human angiographic studies that lowering of serum total and LDL cholesterol levels is followed by regression of atherosclerotic lesions in arteries [1]. It was also shown in humans that with extensive dietary and lifestyle changes it was possible to reduce the most important clinical outcome, coronary morbidity and mortality [2, 3, 4, 5]. In addition, similar results were obtained with a couple of large-scale drug interventions with cholestyramine [6] and nicotinic acid [7]. On the basis of these studies, it could be anticipated that atherosclerosis is a reversible disease.
This paper references
10.1016/S0002-9149(97)00904-1
Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).
T. Pedersen (1998)
10.1056/NEJM199007263230403
Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
E. Reihnér (1990)
Detection of changes in human cholesterol metabolism.
T. Miettinen (1970)
10.1093/ajcn/43.1.92
Serum plant sterols and their relation to cholesterol absorption.
R. Tilvis (1986)
10.1016/s0140-6736(68)92497-5
Employers' liability for cancer of the scrotum.
J. Winch (1968)
10.1161/01.cir.89.3.1333
National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
S. Grundy (1994)
10.1056/NEJM199811053391902
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
A. Tonkin (1998)
10.1016/S0140-6736(81)91338-6
EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASE: Report from the Oslo Study Group of a Randomised Trial in Healthy Men
I. Hjermann (1981)
10.1001/JAMA.279.20.1615
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
J. R. Downs (1998)
10.1016/J.ATHEROSCLEROSISSUP.2004.08.027
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.
T. Pedersen (2004)
10.1161/01.cir.97.15.1440
Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS).
C. Packard (1998)
10.1056/NEJM199907083410202
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
B. Pitt (1999)
10.1001/jama.1984.03350180015009
Lipid Research Clinics Program.
R. Renfrew (1984)
10.1056/NEJM199701163360301
The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
Post Coronary Artery Bypass Graft Trial Investigators (1997)
10.1016/S0002-9149(00)00910-3
Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering.
T. Pedersen (2000)
10.1007/978-94-009-0311-1_54
Noncholesterol Serum Sterols in Scandinavian Simvastatin Survival Study
Tatu Miettinen (1996)
10.1056/NEJM199511163332001
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
J. Shepherd (1995)
10.1001/ARCHINTE.159.22.2661
Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.
S. Haffner (1999)
10.1161/01.CIR.101.2.207
Current perspectives on statins.
D. Maron (2000)
10.1056/NEJM199908123410707
Drug treatment of lipid disorders.
R. Knopp (1999)
10.1161/01.ATV.20.2.500
Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation.
A. Vuorio (2000)
10.1016/0021-9150(94)05474-W
Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination.
H. Vanhanen (1995)
10.2337/diacare.20.4.614
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
K. Pyoeraelae (1997)
10.1126/science.151.3713.1016
Drugs Affecting Lipid Metabolism
D. Kritchevsky (1988)
Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men.
H. Gylling (1996)
10.1016/S0140-6736(72)92208-8
Effect of cholesterol-lowering diet on mortality from coronary heart-disease and other causes. A twelve-year clinical trial in men and women.
M. Miettinen (1972)
10.1136/bmj.316.7138.1127
Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study
T. Miettinen (1998)
10.1007/BF00278470
Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia
H. Vanhanen (1992)
10.1016/S0735-1097(98)81868-8
Basal non-cholesterol sterols reveal a subgroup of 4S not benefitted by simvastatin-induced decrease of recurrent coronary events
T. Miettinen (1998)
Cytochrome P-450 immunolocalization in human liver.
G. Murray (1986)
10.1016/s1053-0770(98)90253-1
Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis
StephenMacMahon (1998)
10.1161/01.ATV.20.5.1340
Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol.
T. Miettinen (2000)
10.1016/0026-0495(92)90050-K
Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man.
H. Vanhanen (1992)
10.1056/NEJM199610033351401
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
F. Sacks (1996)
10.1093/oxfordjournals.aje.a115479
Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population.
T. Miettinen (1990)
10.1016/S0021-9150(97)88911-3
2.P.274 Reduction of cardiovascular events in the elderly by pravastatin (the PATE study): Significance of diabetes mellitus
T. Ishikawa (1997)
10.1161/01.CIR.97.15.1446
Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.
F. Sacks (1998)
10.1007/BF03258191
Inhibition of Dietary Cholesterol Absorption During Lovastatin (Mevinolin) Treatment
T. Miettinen (1990)
10.1161/01.CIR.97.15.1453
Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)
T. Pedersen (1998)
10.1016/S0735-1097(98)00522-1
Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events.
M. Pfeffer (1999)
10.1161/01.CIR.101.5.477
Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
A. Gotto (2000)
10.1161/01.CIR.96.12.4226
Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol.
H. Gylling (1997)
10.1161/01.cir.97.15.1436
Statin trials and goals of cholesterol-lowering therapy.
S. Grundy (1998)
10.1161/01.CIR.96.12.4211
Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)
T. Miettinen (1997)
10.1016/S0735-1097(86)80293-5
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
P. Canner (1986)
10.1056/NEJM199509073331003
Effect of pravastatin on outcomes after cardiac transplantation.
J. Kobashigawa (1995)
10.1056/NEJM199801083380203
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group.
J. Kuivenhoven (1998)
10.1016/0026-0495(89)90252-7
Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men.
T. Miettinen (1989)
10.1161/01.ATV.12.7.807
Lathosterol and other noncholesterol sterols during treatment of hypercholesterolemia with lovastatin alone and with cholestyramine or guar gum.
M. Uusitupa (1992)
Correlation between serum levels of some cholesterol precursors and activity of HMG-CoA reductase in human liver.
I. Björkhem (1987)
10.1016/0014-5793(82)80416-X
Bile Acids and Lipids
G. Haslewood (1982)
10.1016/S0140-6736(89)90828-3
EFFECTS OF CHANGES IN FAT, FISH, AND FIBRE INTAKES ON DEATH AND MYOCARDIAL REINFARCTION: DIET AND REINFARCTION TRIAL (DART)
M. Burr (1989)
10.1161/01.CIR.99.25.3241
Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.
L. Campeau (1999)
10.1007/978-1-4757-1824-9_66
Effect of Diet and Smoking Intervention on the Incidence of Coronary Heart Disease
I. Hjermann (1981)
Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans.
H. Kempen (1988)
10.1161/01.CIR.97.18.1784
Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis Results of the LIPID Atherosclerosis Substudy
S. MacMahon (1998)
10.1161/01.CIR.99.6.779
Mediterranean Diet, Traditional Risk Factors, and the Rate of Cardiovascular Complications After Myocardial Infarction Final Report of the Lyon Diet Heart Study
M. Lorgeril (1999)



Semantic Scholar Logo Some data provided by SemanticScholar